Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · IEX Real-Time Price · USD
0.780
-0.009 (-1.14%)
At close: Jul 2, 2024, 4:00 PM
0.760
-0.020 (-2.55%)
After-hours: Jul 2, 2024, 7:39 PM EDT
Lucid Diagnostics Revenue
Lucid Diagnostics had revenue of $2.98M in the twelve months ending March 31, 2024, with 370.50% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.00M with 124.44% year-over-year growth. In the year 2023, Lucid Diagnostics had annual revenue of $2.43M with 544.03% growth.
Revenue (ttm)
$2.98M
Revenue Growth
+370.50%
P/S Ratio
13.71
Revenue / Employee
$42,614
Employees
70
Market Cap
40.89M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.43M | 2.05M | 544.03% |
Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
Dec 31, 2021 | 500.00K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Inotiv | 552.74M |
Augmedix | 48.70M |
Atara Biotherapeutics | 34.70M |
Dyadic International | 2.26M |
vTv Therapeutics | 1.00M |
LUCD News
- 17 hours ago - Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population - PRNewsWire
- 20 days ago - 4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing - PRNewsWire
- 7 weeks ago - PAVmed Provides Business Update and First Quarter 2024 Financial Results - PRNewsWire
- 7 weeks ago - Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results - PRNewsWire
- 7 weeks ago - Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall - PRNewsWire
- 2 months ago - Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors - PRNewsWire
- 2 months ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 - PRNewsWire
- 2 months ago - Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing - PRNewsWire